Press & Publications

Press release

Accure Therapeutics awarded €1 million from Spanish government to evaluate ACT-03 for post-traumatic epilepsy

Article

The Gelatinase Inhibitor ACT-03 Reduces Gliosis in the Rapid Kindling Rat Model of Epilepsy, and Attenuates Inflammation and Loss of Barrier Integrity In Vitro

Press release

L’agencia per a la Competitivitat de l’Empresa, ACCIÓ, en data 1 de març de 2018 ha atorgat a Iproteos (Accure Therapeutics) la concessió d’una subvenció per les seves aportacions a les teràpies pel Parkinson

Article

Accure Therapeutics presented at EAN the improvement of neurodegeneration with ACT-02 in a preclinical study of Parkinson’s disease

Press release

Oculis Strengthens Leading Ophthalmology Pipeline by In-Licensing Neuroprotective Drug Candidate for Glaucoma from Accure Therapeutics

Article

Accure Therapeutics presented at ECTRIMS four communications reporting the progress of ACT-01 neuroprotective therapy for Multiple Sclerosis

Press release

Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01